临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1029044-16-3

Pexidartinib (PLX3397)

中文名称:吡昔替尼
CAS号:1029044-16-3
分子式: C20H15ClF3N5 分子量: 417.81
产品形式: free base
研发状态: Recruiting
研发用途: Tenosynovial Giant Cell Tumor
研究机构: Daiichi Sankyo Co. Ltd.; Daiichi Sankyo
研发日期: March 15 2021
研发阶段: Phase 2
Pexidartinib (PLX3397) is an oral, potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit (c-Kit), and FLT3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Pexidartinib (PLX3397) induces apoptosis and necrosis with antitumor activity. Phase 3.

CAS: 1028486-01-2

Alisertib (MLN8237)

中文名称:阿立塞替
CAS号:1028486-01-2
分子式: C27H20ClFN4O4 分子量: 518.92
产品形式: free base
研发状态: Completed
研发用途: Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
研究机构: M.D. Anderson Cancer Center
研发日期: June 18 2020
研发阶段: Phase 1
Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

CAS: 10284-63-6

D-Pinitol

中文名称: D-松醇
CAS号:10284-63-6
分子式: C7H14O6 分子量: 194.18
产品形式: free base
研发状态: Completed
研发用途: Type 2 Diabetes; Impaired Glucose Tolerance; Healthy
研究机构: University of Valencia
研发日期: Jan-12
研发阶段: Not Applicable
D-pinitol (Methylinositol, Pinitol, 3-O-Methyl-D-chiro-inositol, D-(+)-Pinitol, Inzitol) is a naturally occurring compound derived from soy and has significant pharmacological activitites such as inhibition of the T-helpercell-1 response, antiviral, larvicidal, antiinflammatory, antihyperlipidemic, cardioprotective, inhibition of ovalbumin-induced airway inflammation and antioxidant.

CAS: 102767-28-2

Levetiracetam (UCB-L059)

中文名称: 左乙拉西坦
CAS号:102767-28-2
分子式: C8H14N2O2 分子量: 170.21
产品形式: free base
研发状态: Not yet recruiting
研发用途: Febrile Convulsion
研究机构: Assiut University
研发日期: June 1 2023
研发阶段: Not Applicable
Levetiracetam (UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam (UCB-L059, SIB-S1) is an agonist of muscarinic acetylcholine receptors (mAChR). Levetiracetam modulates the presynaptic P/Q-type voltage-dependent calcium (Ca2+) channel.

CAS: 1026785-59-0

Lomibuvir (VX-222)

CAS号:1026785-59-0
分子式: C25H35NO4S 分子量: 445.61
产品形式: free base
研发状态: Completed
研发用途: Hepatitis C
研究机构: Vertex Pharmaceuticals Incorporated
研发日期: Aug-09
研发阶段: Phase 1
Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.

CAS: 102625-70-7

Pantoprazole

中文名称: 泮托拉唑
CAS号:102625-70-7
分子式: C16H15F2N3O4S 分子量: 383.37
产品形式: free base
研发状态: Recruiting
研发用途: Pediatric Obesity; NAFLD; GERD
研究机构: Children''s Mercy Hospital Kansas City
研发日期: July 3 2018
研发阶段: Phase 4
Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.